(Reuters) – Bristol Myers Squibb said on Thursday its injectable form of blockbuster cancer drug Opdivo was found to be non-inferior to the approved intravenous form in a late-stage trial for treatment of a type of kidney cancer.
(This story has been refiled to fix a typo in the headline)
(Reporting by Leroy Leo in Bengaluru; Editing by Anil D’Silva)
